South East London Integrated Medicines Optimisation Committee
Formulary recommendation

Reference	**041**
Intervention:	**Lisdexamfetamine dimesylate (Elvanse Adult®) capsules for attention deficit/hyperactivity disorder (ADHD) in ADULTS** (Lisdexamfetamine dimesylate is an inactive pro-drug which breaks down into dexamfetamine. Dexamfetamine is an amphetamine based medicine which increases dopamine and noradrenaline concentration in the synapse)
Date of Decision	**November 2015. Updated December 2022**
Date of Issue:	**December 2015. Re-issued December 2022**
Recommendation:	**Amber 3 – Specialist mental health team initiation and supply. GPs may be asked to take on prescribing under a full shared care agreement.**
Further Information	• Lisdexamfetamine (Elvanse Adult®) is supported for use within South East London for the treatment of adult ADHD in line with NICE guidance as a **first line option or if a 6 week trial of methylphenidate has not been successful**. • Lisdexamfetamine may also be considered for continuation in patients already stabilised on existing amphetamine based therapy, for example patients transitioning from child to adult ADHD services. • Lisdexamfetamine may be preferable to dexamfetamine as it is licensed for use in adult ADHD and is taken once daily. • Lisdexamfetamine has a high risk of diversion and is a Schedule 2 controlled drug. The potential for abuse, misuse or diversion should be considered prior to prescribing. • Refer to the SEL shared care prescribing guideline for complex ADHD in adults and SEL IMOC recommendation 040 – dexamfetamine for adult ADHD for further information.
Shared Care/ Transfer of care required:	Yes
Cost Impact for agreed patient group	• Costs are comparable to current treatments for ADHD for which lisdexamfetamine would be an alternative treatment option, therefore no additional significant budget impact is expected. • Lisdexamfetamine costs less than dexamfetamine at equivalent treatment doses and therefore in addition to convenient dosing, it could be cost saving to the local health economy: – Dexamfetamine at a dose of 10mg-60mg daily (divided doses) cost £644-£3861 per patient per year – Lisdexamfetamine 30mg-70mg daily costs £757-£1,081 per patient per year.
Usage Monitoring & Impact Assessment	**Mental Health Trusts and teams:** • Monitor and submit usage and audit data on request to the Committee • Ensure shared care guideline is implemented and adhered to
	SEL Borough Medicines Teams: • Monitor ePACT2 data and exception reports from GPs if inappropriate prescribing requests are made to primary care

Evidence reviewed	References (from evidence review)
	1. Attention Deficit Hyperactivity Disorder: diagnosis and management. National Institute of Health and Care Excellence Clinical Guideline 72, 2008 2. Faraone, S.V., Biederman, K. Mick, E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychological Medicine 2006 36(2), 159-165. 3. Punja S, Shamseer L, Hartling L et al. (2012) Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews 4. Maneeton N, Maneeton B, Suttajit S et al. A systematic review of randomised controlled trials of lisdexafetamine versus placebo in the treatment of adults with ADHD. European Neuropsychopharmacology, October 2014 24 (s208) 5. Castells X, Ramos-Quiroga J, Bosch R et al (2011). Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults (Review). Cochrane Database of Systematic Reviews. 6. Adler L, Dirks B, Deas P et al. Lisdexafetamine dimesylate in adults with ateention deficit/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo controlled study. Journal of Clinical Psychiatry 2013 74 7 p694-702. 7. Adler L, Goodman D, Kollins S et al. Double-blind, placebo controlled study of the efficacy and safety of lisdexafetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry 2008 69 9 p1364-1373 8. Weisler R, Young J, Mattingly G et al. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectrums 2009 14 10 p573-585. 9. Brams M, Weisler R, Findling R et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. Journal of Clinical Psychiatry 2012 73 7 p977-983. 10. Wigal T, Brams M, Gasior M et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment. Behavioural and Brain Functions 2010 6 34. 11. Lisdexamfetamine dimesylate 30mg, 50mg and 70mg hard capsules (Elvanse Adult) 1079/15. The Scottish Medicines Consortium, July 2015. 12. Summary of Product Characterisitics, Elvanse Adult (lisdexafetamine). Available online at: http://www.medicines.org.uk/emc/medicine/30377 <accessed 01/11/2015> 13. Public Assessment Report, Elvanse Adult (lisdexamfetamine dimesylate). The Medicines and Healthcare Products Regulatory Agency 2015 14. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate. National Institute of Health and Care Excellence Evidence Summary New Medicine 19, July 2013 15. The Drug Tariff, October 2015 16. NICE Costing report for Attention Deficit Hyperactivity Disorder (CG72). Available online at: http://www.nice.org.uk/guidance/cg72/resources <accessed: 04.11.2015> 17. Lisdexamfetamine dimesylate (Elvanse Adult) Advice 2615, The All Wales Medicines Strategy Group September 2015 18. Recommendation 005: Lisdexafetamine dimesylate for children with ADHD. The South East London Area Prescribing Committee, October 2013.

NOTES:

a) SEL IMOC recommendations and minutes are available publicly via the website.

b) This SEL IMOC recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued.

c) Not to be used for commercial or marketing purposes. Strictly for use within the NHS